WO2010050787A3 - 스프레이 가능한 캡슐화된 기능성 미립자 조성물 및 그 제조방법 - Google Patents

스프레이 가능한 캡슐화된 기능성 미립자 조성물 및 그 제조방법 Download PDF

Info

Publication number
WO2010050787A3
WO2010050787A3 PCT/KR2009/006365 KR2009006365W WO2010050787A3 WO 2010050787 A3 WO2010050787 A3 WO 2010050787A3 KR 2009006365 W KR2009006365 W KR 2009006365W WO 2010050787 A3 WO2010050787 A3 WO 2010050787A3
Authority
WO
WIPO (PCT)
Prior art keywords
spraying
preparation
fine particle
composition capable
particle composition
Prior art date
Application number
PCT/KR2009/006365
Other languages
English (en)
French (fr)
Other versions
WO2010050787A2 (ko
Inventor
최진석
이영우
김준호
심은영
Original Assignee
주식회사 바이오레인
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 바이오레인 filed Critical 주식회사 바이오레인
Priority to JP2011534399A priority Critical patent/JP2012506903A/ja
Priority to US13/126,060 priority patent/US20110206771A1/en
Priority to CN2009801432048A priority patent/CN102202657A/zh
Priority to EP09823867A priority patent/EP2351556A2/en
Publication of WO2010050787A2 publication Critical patent/WO2010050787A2/ko
Publication of WO2010050787A3 publication Critical patent/WO2010050787A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0076—Sprayable compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A61K9/5057—Gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Materials Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

우수한 지혈 및 상처보호 효과를 기대할 수 있고, 환자 스스로 처치 가능할 뿐만 아니라, 체내용으로 사용되는 경우 에어건(air-gun)을 이용하여 수술 시 넓은 상처에 빠르게 도포 가능하고 빠른 지혈 효과를 기대할 수 있다.
PCT/KR2009/006365 2008-10-31 2009-10-30 스프레이 가능한 캡슐화된 기능성 미립자 조성물 및 그 제조방법 WO2010050787A2 (ko)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2011534399A JP2012506903A (ja) 2008-10-31 2009-10-30 スプレー可能なカプセル化された機能性微粒子組成物及びその製造方法
US13/126,060 US20110206771A1 (en) 2008-10-31 2009-10-30 Encapsulated functional fine particle composition capable of spraying and preparation method thereof
CN2009801432048A CN102202657A (zh) 2008-10-31 2009-10-30 能喷雾的胶囊化的功能性细颗粒组合物及其制备方法
EP09823867A EP2351556A2 (en) 2008-10-31 2009-10-30 Encapsulated functional fine particle composition capable of spraying and preparation method thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2008-0108042 2008-10-31
KR1020080108042A KR20100048751A (ko) 2008-10-31 2008-10-31 스프레이 가능한 캡슐화된 기능성 미립자 조성물과 그 제조방법

Publications (2)

Publication Number Publication Date
WO2010050787A2 WO2010050787A2 (ko) 2010-05-06
WO2010050787A3 true WO2010050787A3 (ko) 2010-08-12

Family

ID=42129494

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/006365 WO2010050787A2 (ko) 2008-10-31 2009-10-30 스프레이 가능한 캡슐화된 기능성 미립자 조성물 및 그 제조방법

Country Status (6)

Country Link
US (1) US20110206771A1 (ko)
EP (1) EP2351556A2 (ko)
JP (1) JP2012506903A (ko)
KR (1) KR20100048751A (ko)
CN (1) CN102202657A (ko)
WO (1) WO2010050787A2 (ko)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9327037B2 (en) 2011-02-08 2016-05-03 The Johns Hopkins University Mucus penetrating gene carriers
US9149511B2 (en) * 2011-06-30 2015-10-06 Ethicon, Inc. Procoagulant peptides and their derivatives and uses therefor
JP6099098B2 (ja) * 2011-11-17 2017-03-22 国立大学法人富山大学 生理活性物質徐放制御組成物
CA2849288C (en) * 2011-11-21 2016-03-22 Innotherapy Inc. Hydrogel comprising catechol group-coupled chitosan or polyamine and poloxamer comprising thiol group coupled to end thereof, preparation method thereof, and hemostat using same
SG10201509573VA (en) * 2011-11-25 2015-12-30 Otsuka Pharma Co Ltd Pharmaceutical composition useful for adhesion prevention or hemostasis
WO2014124006A1 (en) * 2013-02-05 2014-08-14 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
US9775853B2 (en) 2013-03-15 2017-10-03 Biomet Manufacturing, Llc. Hemostatic compositions and methods
WO2015175545A1 (en) 2014-05-12 2015-11-19 The Johns Hopkins University Highly stable biodegradable gene vector platforms for overcoming biological barriers
US10485757B2 (en) 2015-01-27 2019-11-26 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
CN105925173B (zh) * 2016-04-15 2018-03-23 淮阴工学院 一种铜离子螯合型纳米粒子生物涂层的制备方法
CN106421871A (zh) * 2016-09-29 2017-02-22 广州赛莱拉干细胞科技股份有限公司 一种喷雾型医用胶原贴敷料及其制备方法
KR102039552B1 (ko) * 2017-10-23 2019-11-01 이재혁 상처 부위에 도포되는 발포성 밴드
WO2020012954A1 (ja) * 2018-07-10 2020-01-16 パナソニックＩｐマネジメント株式会社 ミスト発生装置
EP3646893A1 (en) * 2018-10-29 2020-05-06 Solvay Sa Solid spray composition
KR102093839B1 (ko) * 2019-05-28 2020-05-04 (주)다림티센 지혈용 조성물 및 이를 포함하는 용기
CN111662593B (zh) * 2020-06-04 2022-08-09 广东康烯科技有限公司 Ptc石墨烯基导电油墨的制备方法及ptc石墨烯基导电油墨
CN111662594B (zh) * 2020-06-04 2022-08-09 广东康烯科技有限公司 Ptc石墨烯基导电油墨的制备方法及ptc石墨烯基导电油墨
CN112386738A (zh) * 2020-11-18 2021-02-23 程信强 一种多孔甲壳素止血微球的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000071079A2 (en) * 1999-05-21 2000-11-30 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
KR100445146B1 (ko) * 1998-05-27 2004-08-18 유로-셀띠끄 소시에떼 아노님 항염증용 제제, 특히 하부호흡기의 창상치료 촉진용 약제및/또는 소독 약제

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3984664B2 (ja) * 1995-12-22 2007-10-03 日清紡績株式会社 創傷被覆材
US20030211157A1 (en) * 1996-05-06 2003-11-13 Simon David Lew Semi-sol delivery blend for water soluble molecules
US6706690B2 (en) 1999-06-10 2004-03-16 Baxter Healthcare Corporation Hemoactive compositions and methods for their manufacture and use
GB2337201B (en) 1997-01-30 2001-02-14 Alpenstock Holdings Ltd Haemostatic aerosol composition
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6432415B1 (en) 1999-12-17 2002-08-13 Axrix Laboratories, Inc. Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces
CN100398159C (zh) 2001-04-30 2008-07-02 北京纺织科学研究所 水溶性纤维素醚化衍生物止血材料
JP3805654B2 (ja) * 2001-08-29 2006-08-02 株式会社ネクスト 止血・癒着防止性のバイオポリマーの微細粒子
EP1773414A1 (en) 2004-07-08 2007-04-18 Alltracel Development Services Limited A delivery system for controlling the bleeding of skin wounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100445146B1 (ko) * 1998-05-27 2004-08-18 유로-셀띠끄 소시에떼 아노님 항염증용 제제, 특히 하부호흡기의 창상치료 촉진용 약제및/또는 소독 약제
WO2000071079A2 (en) * 1999-05-21 2000-11-30 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JEONG, B. ET AL.: "In situ gelation of PEG-PLGA-PEG triblock copolymer aqueous solutions and degradation thereof.", JOURAL OF BIOMEDICAL MATERIALS RESEARCH, vol. 50, 2000, pages 171 - 177, XP008146655 *
MALLARDE, D. ET AL.: "PLGA-PEG microspheres of teverelix: influence of polymer type on microsphere characteristics and on teverelix in vitro release", INT. J. PHARM., vol. 261, 2003, pages 69 - 80, XP001181904 *

Also Published As

Publication number Publication date
US20110206771A1 (en) 2011-08-25
JP2012506903A (ja) 2012-03-22
WO2010050787A2 (ko) 2010-05-06
KR20100048751A (ko) 2010-05-11
EP2351556A2 (en) 2011-08-03
CN102202657A (zh) 2011-09-28

Similar Documents

Publication Publication Date Title
WO2010050787A3 (ko) 스프레이 가능한 캡슐화된 기능성 미립자 조성물 및 그 제조방법
WO2011061330A3 (de) Verwendung physiologischer kühlwirkstoffe und mittel enthaltend solche wirkstoffe
WO2010027792A8 (en) Treatment of sweating and hyperhidrosis
WO2008089087A3 (en) Tablet-in-tablet compositions
WO2011035062A3 (en) Spray dried human plasma
WO2006083630A3 (en) Diiodomethyl-p-tolylsulfone as a particulate dispersion in a liquid solvent in combination with an anti-dandruff active
WO2009149369A3 (en) Acne treatment compositions comprising nanosilver and uses
WO2009101503A3 (fr) Utilisation de substances actives naturelles dans des compositions cosmétiques ou thérapeutiques
WO2010083379A3 (en) Beta-amino ester compounds and uses thereof
WO2012002669A3 (en) Cosmetic composition for preventing skin aging
WO2008036763A3 (en) Tissue adhesive compositions and methods thereof
WO2010072787A3 (en) A composition comprising a retinoid and method of treating skin conditions
WO2012054387A3 (en) Apparatus and processes for applying substances within mammalian tissue
WO2008151749A3 (de) Aktivierbare diagnostische und therapeutische verbindung
WO2014080199A3 (en) Preservatives
WO2011126250A3 (ko) Pde5 억제제를 함유하는 피부 주름 개선용 조성물
WO2013020094A3 (en) Novel hemostatic patch and uses thereof
WO2008107092A3 (en) Use of derivatives of 4-hydroxyphenoxy acetic acid
WO2009043991A3 (fr) Utlisation d'un principe actif issu du lin dans une composition destinee a activer le cytochrome c
WO2011042902A3 (en) Microcapsules comprising benzoyl peroxide and topical compositions comprising them
WO2010062122A9 (ko) 동맥경화 예방 또는 치료용 조성물
WO2012038469A3 (en) Cosmetic composition
WO2009095615A3 (fr) Utilisation d'un actif issu de cyperus esculentus pour son action cutanee anti-age
WO2009027382A3 (de) Sprühfähige zusammensetzung enthaltend extrakt aus rotem weinlaub
WO2008019782A3 (de) Dispersionen von nanoharnstoffen. enthaltend wirkstoffe

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980143204.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09823867

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 13126060

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2011534399

Country of ref document: JP

Ref document number: 2009823867

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE